Reference

A computational approach to the synthesis of dirithromycin

A computational approach to the synthesis of dirithromycin. Duran, Dilek; Aviyente, Viktorya; Baysal, Canan (Chemistry Department, Faculty of Art and Sciences, Bogazici University, Istanbul 34342, Turk.In this study， 62013-04-1 and 111964-99-9 are also used.). Journal of Molecular Modeling, 10(2), 94-101 (English) 2004 Springer-Verlag. URL: http://springerlink.metapress.com/media/320E3XKWLN6UNM2G9M7J /Contributions/K/P/J/Q/KPJQ14L3NQTP6GA3.pdf. CODEN: JMMOFK. ISSN: 0948-5023. DOCUMENT TYPE: Journal; (online computer file) CA Section: 33 (Carbohydrates) Section cross-reference(s): 22, 26 Dirithromycin is a macrolide antibiotic derived from erythromycin A. Dirithromycin is synthesized by the condensation of 9(S)-erythromycylamine with 2-(2-methoxyethoxy)acetaldehyde. To gain insight into the synthesis, the condensation mechanism has been analyzed computationally by the AM1 method in the gas phase. First, the formation of the Schiff bases of dirithromycin and epidirithromycin from 9(S)-erythromycylamine and 2-(2-methoxyethoxy)-acetaldehyde were modeled. Then, the tautomerization of the Schiff bases to dirithromycin and epidirithromycin were considered. Finally, the epimerization of the Schiff base of epidirithromycin to the Schiff base of dirithromycin was investigated. Our results show that, even though carbinolamine forms faster for epidirithromycin than the corresponding structure for dirithromycin, dirithromycin is the major product of the synthesis. .

Dirithromycin versus amoxiclav in the treatment of acute exacerbations of chronic bronchitis

Dirithromycin versus amoxiclav in the treatment of acute exacerbations of chronic bronchitis. Van Royen, P.; Betz, W.; Heyrman, J.; Taziaux, P.; Van Den Haute, M.; Poelman, M. (Centre for General Medicine, University of Antwerp, Belg.). Journal of International Medical Research, 25(1), 33-40 (English) 1997 Cambridge Medical Publications Ltd.Several reagents such as 62013-04-1 is used here. CODEN: JIMRBV. ISSN: 0300-0605. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) A total of 334 patients with acute exacerbation of chronic bronchitis were treated with either dirithromycin for 5 days (n = 169) or amoxiclav for 7-10 days (n = 165) in an open randomized trial. The efficacy and tolerability of the two drugs were compared. There was no statistically significant difference in outcome between the two treatment arms. Clin. success (cure or improvement) was obtained in 94.5% and 93.1% of patients treated with dirithromycin and amoxiclav, resp. Adverse events (mostly gastrointestinal) occurred in both groups, but led to discontinuation of treatment (in only seven patients). We conclude that the two drugs are equally efficacious and safe. .